Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Anaptysbio (ANAB) over the last 10 years, with Q3 2025 value amounting to $331.8 million.

  • Anaptysbio's Other Non-Current Liabilities fell 534.0% to $331.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $331.8 million, marking a year-over-year decrease of 534.0%. This contributed to the annual value of $353.4 million for FY2024, which is 1371.24% up from last year.
  • Latest data reveals that Anaptysbio reported Other Non-Current Liabilities of $331.8 million as of Q3 2025, which was down 534.0% from $331.4 million recorded in Q2 2025.
  • Over the past 5 years, Anaptysbio's Other Non-Current Liabilities peaked at $362.0 million during Q2 2024, and registered a low of $251.1 million during Q4 2021.
  • Its 5-year average for Other Non-Current Liabilities is $311.4 million, with a median of $310.5 million in 2023.
  • In the last 5 years, Anaptysbio's Other Non-Current Liabilities skyrocketed by 2123.52% in 2022 and then tumbled by 845.9% in 2025.
  • Anaptysbio's Other Non-Current Liabilities (Quarter) stood at $251.1 million in 2021, then grew by 21.24% to $304.4 million in 2022, then increased by 2.1% to $310.8 million in 2023, then grew by 13.71% to $353.4 million in 2024, then fell by 6.11% to $331.8 million in 2025.
  • Its last three reported values are $331.8 million in Q3 2025, $331.4 million for Q2 2025, and $330.4 million during Q1 2025.